Standard BioTools Inc.
NasdaqGS:LAB Rapporto sulle azioni
Cap. di mercato: US$763.1m
Standard BioTools Performance dei guadagni passati
Il passato criteri di controllo 0/6 Gli utili di Standard BioTools sono diminuiti a un tasso medio annuo di -21.4%, mentre il settore Life Sciences ha visto gli utili crescere a un tasso medio annuo di 11.7%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 0.4%.
Informazioni chiave
-21.4%
Tasso di crescita degli utili
-5.6%
Tasso di crescita dell'EPS
Life Sciences Crescita del settore 21.5% Tasso di crescita dei ricavi -0.4% Rendimento del capitale proprio -25.5% Margine netto -109.4% Ultimo aggiornamento sui guadagni 30 Sep 2024
Aggiornamenti sulle prestazioni recenti
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 01
Standard BioTools Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 16
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 01
Standard BioTools Inc. to Report Q2, 2024 Results on Jul 31, 2024 Jul 17
Standard BioTools Inc. to Report Q1, 2024 Results on May 08, 2024 Apr 27
Standard BioTools Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
Mostra tutti gli aggiornamenti Standard BioTools Inc. Announces the Appointment of Alex Kim as Chief Financial Officer, Effective November 11, 2024
Standard BioTools Inc. Reiterates Revenue Guidance for Full Year 2024 Nov 02
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 01
Standard BioTools (NASDAQ:LAB) Has Debt But No Earnings; Should You Worry? Oct 26
Standard BioTools Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 16
Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher Sep 14
Consensus revenue estimates decrease by 15% Aug 07
Newsflash: Standard BioTools Inc. (NASDAQ:LAB) Analysts Have Been Trimming Their Revenue Forecasts Aug 05
No longer forecast to breakeven Aug 02
Standard BioTools Inc. Revises Revenue Guidance for the Full Year 2024 Aug 02
New minor risk - Share price stability Aug 01
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 01
Standard BioTools Inc. Announces Chief Financial Officer Changes Aug 01
Revenues Tell The Story For Standard BioTools Inc. (NASDAQ:LAB) As Its Stock Soars 42% Jul 26
Forecast to breakeven in 2026 Jul 25
High number of new and inexperienced directors Jul 25
Standard BioTools Inc. to Report Q2, 2024 Results on Jul 31, 2024 Jul 17
Standard BioTools Inc., Annual General Meeting, Jun 27, 2024 May 24
Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024 May 10
Standard BioTools Inc. to Report Q1, 2024 Results on May 08, 2024 Apr 27 Standard BioTools Inc. Announces Operational Restructuring Plan Apr 26
Now 21% undervalued Apr 18
Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging Apr 09
Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)? Apr 09
Consensus EPS estimates upgraded to US$0.43 loss Apr 03
Chief Strategy Officer notifies of intention to sell stock Mar 20
Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB) Mar 06
Forecast to breakeven in 2026 Mar 03
Standard BioTools Inc. Provides Revenue Guidance for the Full Year 2024 Mar 01
New major risk - Financial position Feb 29
Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable Feb 17
Standard BioTools Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt? Jan 12
New major risk - Revenue and earnings growth Jan 09
Standard Biotools Inc. Provides Revenue Guidance for the Fourth Quarter and full year 2023 Jan 09
SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others. Jan 06 SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10
Standard BioTools Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 26 SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction. Oct 06
SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction. Oct 05
Is Standard BioTools (NASDAQ:LAB) A Risky Investment? Aug 13
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
Standard BioTools Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
High number of new directors Jun 22
Senior VP & CFO recently bought US$194k worth of stock May 24
Standard BioTools Inc. Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System May 19 Standard BioTools Inc. Appoints Jeffrey Black as Chief Financial Officer
First quarter 2023 earnings released: US$0.21 loss per share (vs US$0.99 loss in 1Q 2022) May 11
Standard BioTools Inc. Announces Retirement of Gerhard Burbach as Member of the Board of Directors May 05
Chief Financial Officer exercised options and sold US$58k worth of stock Mar 01
Standard BioTools Inc. Provides Earnings Guidance for the Year 2023 Feb 16
Full year 2022 earnings released: US$2.43 loss per share (vs US$0.78 loss in FY 2021) Feb 16
Standard BioTools Inc. to Report Q4, 2022 Results on Feb 14, 2023 Feb 01
Standard Biotools Inc. Appoints Betsy Jensen as Chief Human Resources Officer Jan 04
Standard BioTools Inc. (NasdaqGS:LAB) announces an Equity Buyback for $20 million worth of its shares. Nov 29
Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021) Nov 10
Standard BioTools Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform Oct 07
Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.23 loss in 2Q 2021) Aug 10
Standard BioTools Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2022 Aug 10
Standard BioTools Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 26
Standard BioTools Inc. Announces Resignation of Nicholas Khadder as Senior Vice President, General Counsel and Corporate Secretary Jul 09
Standard Biotools Inc. Announces Resignation of Bradley Kreger, Senior Vice President, Global Operations Jun 29
Standard BioTools Inc.(NasdaqGS:LAB) dropped from Russell Microcap Value Index Jun 26
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 06
Standard BioTools Inc., Annual General Meeting, Jun 15, 2022 May 02
Price target decreased to US$6.00 Apr 27
Standard BioTools Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 23
Standard Biotools Inc. Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging Apr 12
Independent Director exercised options to buy US$80k worth of stock. Apr 06 Fluidigm Corporation Announces Board Changes
Fluidigm Corporation Announces Management Changes Mar 30
Price target decreased to US$6.00 Feb 24
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 19
Fluidigm Corporation: Investment Opportunity Jan 26
Ripartizione dei ricavi e delle spese
Come Standard BioTools guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate NasdaqGS:LAB Ricavi, spese e utili (USD Millions ) Data Ricavi Guadagni Spese G+A Spese di R&S 30 Sep 24 156 -171 140 55 30 Jun 24 136 -165 128 26 31 Mar 24 127 -136 113 35 31 Dec 23 106 -75 88 26 30 Sep 23 105 -76 86 51 30 Jun 23 105 -84 87 34 31 Mar 23 97 -131 93 40 31 Dec 22 98 -190 102 34 30 Sep 22 109 -179 105 2 30 Jun 22 112 -163 107 0 31 Mar 22 124 -117 102 0 31 Dec 21 131 -59 99 0 30 Sep 21 137 -68 108 0 30 Jun 21 148 -60 106 0 31 Mar 21 143 -56 103 0 31 Dec 20 138 -53 98 0 30 Sep 20 126 -48 85 0 30 Jun 20 113 -55 83 0 31 Mar 20 115 -55 84 0 31 Dec 19 117 -65 84 0 30 Sep 19 117 -67 88 8 30 Jun 19 120 -69 87 15 31 Mar 19 118 -71 84 23 31 Dec 18 113 -59 80 0 30 Sep 18 108 -55 74 53 30 Jun 18 104 -56 74 45 31 Mar 18 102 -57 76 38 31 Dec 17 102 -61 80 31 30 Sep 17 99 -68 86 0 30 Jun 17 97 -72 87 0 31 Mar 17 101 -73 90 0 31 Dec 16 104 -76 93 38 30 Sep 16 110 -71 93 0 30 Jun 16 117 -61 91 0 31 Mar 16 117 -57 88 0 31 Dec 15 115 -53 83 0 30 Sep 15 117 -51 78 0 30 Jun 15 118 -56 79 0 31 Mar 15 117 -53 75 0 31 Dec 14 116 -53 71 0 30 Sep 14 104 -47 66 0 30 Jun 14 92 -37 58 0 31 Mar 14 82 -28 52 0 31 Dec 13 71 -17 48 0
Guadagni di qualità: LAB al momento non è redditizia.
Margine di profitto in crescita: LAB al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: LAB non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 21.4% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di LAB nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: LAB non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Life Sciences ( -4.7% ).
Rendimento del capitale proprio
ROE elevato: LAB ha un Return on Equity negativo ( -25.46% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
